



## Clinical trial results:

### An open-label, multi-center, expanded access study of RAD001 in patients with angiomyolipoma associated with tuberous sclerosis complex (TSC)

#### Summary

|                          |                   |
|--------------------------|-------------------|
| EudraCT number           | 2012-005397-63    |
| Trial protocol           | ES                |
| Global end of trial date | 29 September 2014 |

#### Results information

|                                |              |
|--------------------------------|--------------|
| Result version number          | v1 (current) |
| This version publication date  | 14 June 2020 |
| First version publication date | 14 June 2020 |

#### Trial information

##### Trial identification

|                       |              |
|-----------------------|--------------|
| Sponsor protocol code | CRAD001MES12 |
|-----------------------|--------------|

##### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

#### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Novartis Farmacéutica, S.A   |
| Sponsor organisation address | Gran Vía de les Corts Catalanes, 764, Barcelona, Spain, 08013  |
| Public contact               | Departamento Médico de Oncología, Novartis Farmacéutica, S.A, 00 34900353036, <a href="mailto:eecc.novartis@novartis.com">eecc.novartis@novartis.com</a> |
| Scientific contact           | Departamento Médico de Oncología, Novartis Farmacéutica, S.A, 00 34900353036, <a href="mailto:eecc.novartis@novartis.com">eecc.novartis@novartis.com</a> |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

---

**Results analysis stage**

|  |                   |
|--|-------------------|
| Analysis stage                                       | Final             |
| Date of interim/final analysis                       | 29 September 2014 |
| Is this the analysis of the primary completion data? | No                |
| Global end of trial reached?                         | Yes               |
| Global end of trial date                             | 29 September 2014 |
| Was the trial ended prematurely?                     | No                |

Notes:

---

**General information about the trial**

Main objective of the trial:

To evaluate the dose-limiting safety of everolimus in subjects with angiomyolipoma associated with TSC.

Protection of trial subjects:

This study was conducted in compliance with Good Clinical Practice (GCP), including the archiving of essential documents.

Background therapy: -

Evidence for comparator: -

|   |             |
|---|-------------|
| Actual start date of recruitment                          | 20 May 2013 |
| Long term follow-up planned                               | No          |
| Independent data monitoring committee (IDMC) involvement? | No          |

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

|                                      |           |
|--------------------------------------|-----------|
| Country: Number of subjects enrolled | Spain: 19 |
| Worldwide total number of subjects   | 19        |
| EEA total number of subjects         | 19        |

Notes:

---

**Subjects enrolled per age group**

|   |    |
|---|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 0  |
| Children (2-11 years)                     | 0  |
| Adolescents (12-17 years)                 | 0  |
| Adults (18-64 years)                      | 19 |
| From 65 to 84 years                       | 0  |
| 85 years and over                         | 0  |

## Subject disposition

### Recruitment

Recruitment details:

Subjects were enrolled at 15 study centres in Spain.

### Pre-assignment

Screening details:

Subjects enrolled in this study were diagnosed with angiomyolipoma (AML) associated with TSC.

### Period 1

|                              |                                 |
|------------------------------|---------------------------------|
| Period 1 title               | Overall Period (overall period) |
| Is this the baseline period? | Yes                             |
| Allocation method            | Not applicable                  |
| Blinding used                | Not blinded                     |

### Arms

|                  |            |
|------------------|------------|
| <b>Arm title</b> | Everolimus |
|------------------|------------|

Arm description:

Everolimus was administered following an oral daily continuous regimen of two 5 milligram (mg) tablets (10 mg, total daily dose) once a day at the same time everyday, either always with food or without food.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | Everolimus   |
| Investigational medicinal product code | RAD001       |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

The study drug was administered at a daily dose of two 5 mg tablets (10 mg, total daily dose) once a day.

|                                       |            |
|---------------------------------------|------------|
| <b>Number of subjects in period 1</b> | Everolimus |
| Started                               | 19         |
| Completed                             | 19         |

## Baseline characteristics

### Reporting groups

|                       |            |
|-----------------------|------------|
| Reporting group title | Everolimus |
|-----------------------|------------|

Reporting group description:

Everolimus was administered following an oral daily continuous regimen of two 5 milligram (mg) tablets (10 mg, total daily dose) once a day at the same time everyday, either always with food or without food.

| Reporting group values                                | Everolimus | Total |  |
|---|------------|-------|--|
| Number of subjects                                    | 19         | 19    |  |
| Age categorical                                       |            |       |  |
| Units: Subjects                                       |            |       |  |
| In utero  | 0          | 0     |  |
| Preterm newborn infants<br>(gestational age < 37 wks) | 0          | 0     |  |
| Newborns (0-27 days)                                  | 0          | 0     |  |
| Infants and toddlers (28 days-23<br>months)           | 0          | 0     |  |
| Children (2-11 years)                                 | 0          | 0     |  |
| Adolescents (12-17 years)                             | 0          | 0     |  |
| Adults (18-64 years)                                  | 19         | 19    |  |
| From 65-84 years                                      | 0          | 0     |  |
| 85 years and over                                     | 0          | 0     |  |
| Age continuous  |            |       |  |
| Units: years  |            |       |  |
| median  | 38         |       |  |
| full range (min-max)                                  | 20 to 62   | -     |  |
| Gender categorical                                    |            |       |  |
| Units: Subjects                                       |            |       |  |
| Female  | 13         | 13    |  |
| Male  | 6          | 6     |  |
| Race  |            |       |  |
| Units: Subjects                                       |            |       |  |
| Caucasian   | 19         | 19    |  |

## End points

### End points reporting groups

|   |            |
|---|------------|
| Reporting group title   | Everolimus |
| Reporting group description:<br>Everolimus was administered following an oral daily continuous regimen of two 5 milligram (mg) tablets (10 mg, total daily dose) once a day at the same time everyday, either always with food or without food. |            |

### Primary: Number of Subjects With Dose-limiting Safety of Everolimus

|  |   |
|--|---|
| End point title  | Number of Subjects With Dose-limiting Safety of Everolimus <sup>[1]</sup> |
| End point description:<br>Safety population included all subjects who received at least one dose of study drug and had at least one post-baseline safety assessment. |   |
| End point type   | Primary   |
| End point timeframe:<br>Up to approximately 16 months  |   |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this primary outcome measure

| End point values                          | Everolimus      |  |  |  |
|---|-----------------|--|--|--|
| Subject group type                        | Reporting group |  |  |  |
| Number of subjects analysed               | 19              |  |  |  |
| Units: subjects                           |                 |  |  |  |
| Dose reduction                            | 3               |  |  |  |
| Temporary interruption                    | 3               |  |  |  |
| Dose reduction and Temporary interruption | 2               |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Response rate : Percentage of Subjects With Response of Angiomyolipoma to Everolimus

|   |  |
|---|--|
| End point title   | Response rate : Percentage of Subjects With Response of Angiomyolipoma to Everolimus |
| End point description:<br>Tumour response was assessed radiologically using magnetic resonance imaging (MRI) or computerised axial tomography (CT) scans. Tumour evaluations were recommended to be performed for all subjects, a renal MRI/CT scan on weeks 12, 24 and 48 following the start of treatment (with a $\pm 7$ window), then every year unless the observation of angiomyolipoma response required a confirmation of a second scan approximately 12 weeks after (and not prior to 8 weeks after), and at the time of the study drug withdrawal. The AML radiological response was assessed following the predefined response criteria. Full Analysis Set included all subjects who received at least one dose of everolimus. |  |
| End point type  | Secondary  |

End point timeframe:

Until disease progression, unacceptable toxicity, death, discontinuation from the study or until drug becomes commercially available in Spain or until 20 May 2014

|                               |                 |  |  |  |
|-------------------------------|-----------------|--|--|--|
| <b>End point values</b>       | Everolimus      |  |  |  |
| Subject group type            | Reporting group |  |  |  |
| Number of subjects analysed   | 19              |  |  |  |
| Units: percentage of subjects |                 |  |  |  |
| number (not applicable)       | 47.37           |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Adverse Events and Serious Adverse Events

|                 |   |
|-----------------|---|
| End point title | Number of Subjects With Adverse Events and Serious Adverse Events |
|-----------------|---|

End point description:

Safety population included all subjects who received at least one dose of RAD001 and had at least one post-baseline safety assessment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately 16 months

|                             |                 |  |  |  |
|-----------------------------|-----------------|--|--|--|
| <b>End point values</b>     | Everolimus      |  |  |  |
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 19              |  |  |  |
| Units: subjects             |                 |  |  |  |
| Adverse events              | 19              |  |  |  |
| Serious adverse events      | 1               |  |  |  |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected from first dose of study treatment until 28 days following the last dose of study treatment.

Adverse event reporting additional description:

Any sign or symptom that occurs during study treatment plus the 28 days post-treatment

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 17.1 |
|--------------------|------|

### Reporting groups

|                       |            |
|-----------------------|------------|
| Reporting group title | Everolimus |
|-----------------------|------------|

Reporting group description:

Everolimus was administered following an oral daily continuous regimen of two 5 milligram (mg) tablets (10 mg, total daily dose) once a day at the same time everyday, either always with food or without food.

| Serious adverse events                            | Everolimus     |  |  |
|---|----------------|--|--|
| Total subjects affected by serious adverse events |                |  |  |
| subjects affected / exposed                       | 1 / 19 (5.26%) |  |  |
| number of deaths (all causes)                     | 0              |  |  |
| number of deaths resulting from adverse events    | 0              |  |  |
| Respiratory, thoracic and mediastinal disorders   |                |  |  |
| Pneumonia   |                |  |  |
| subjects affected / exposed                       | 1 / 19 (5.26%) |  |  |
| occurrences causally related to treatment / all   | 1 / 1          |  |  |
| deaths causally related to treatment / all        | 0 / 0          |  |  |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events  | Everolimus        |  |  |
|---|-------------------|--|--|
| Total subjects affected by non-serious adverse events               |                   |  |  |
| subjects affected / exposed   | 19 / 19 (100.00%) |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                   |  |  |
| Ovarian cyst  |                   |  |  |
| subjects affected / exposed   | 1 / 19 (5.26%)    |  |  |
| occurrences (all)   | 1                 |  |  |

|  |                 |  |  |
|--|-----------------|--|--|
| Vascular disorders                                   |                 |  |  |
| Hypertension   |                 |  |  |
| subjects affected / exposed                          | 6 / 19 (31.58%) |  |  |
| occurrences (all)                                    | 6               |  |  |
| Dizziness  |                 |  |  |
| subjects affected / exposed                          | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                                    | 2               |  |  |
| Surgical and medical procedures                      |                 |  |  |
| Polypectomy  |                 |  |  |
| subjects affected / exposed                          | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| General disorders and administration site conditions |                 |  |  |
| Mucosal inflammation                                 |                 |  |  |
| subjects affected / exposed                          | 4 / 19 (21.05%) |  |  |
| occurrences (all)                                    | 7               |  |  |
| Asthenia   |                 |  |  |
| subjects affected / exposed                          | 2 / 19 (10.53%) |  |  |
| occurrences (all)                                    | 3               |  |  |
| Pyrexia  |                 |  |  |
| subjects affected / exposed                          | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                                    | 2               |  |  |
| Mucosal dryness                                      |                 |  |  |
| subjects affected / exposed                          | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Immune system disorders                              |                 |  |  |
| Hypersensitivity                                     |                 |  |  |
| subjects affected / exposed                          | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Reproductive system and breast disorders             |                 |  |  |
| Amenorrhoea  |                 |  |  |
| subjects affected / exposed                          | 3 / 19 (15.79%) |  |  |
| occurrences (all)                                    | 3               |  |  |
| Menstrual disorder                                   |                 |  |  |
| subjects affected / exposed                          | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                                    | 3               |  |  |
| Menorrhagia  |                 |  |  |



|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed                     | 2 / 19 (10.53%) |  |  |
| occurrences (all)                               | 2               |  |  |
| Dysmenorrhoea                                   |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Respiratory, thoracic and mediastinal disorders |                 |  |  |
| Catarrh   |                 |  |  |
| subjects affected / exposed                     | 3 / 19 (15.79%) |  |  |
| occurrences (all)                               | 4               |  |  |
| Pharyngitis                                     |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 3               |  |  |
| Nasopharyngitis                                 |                 |  |  |
| subjects affected / exposed                     | 2 / 19 (10.53%) |  |  |
| occurrences (all)                               | 3               |  |  |
| Cough   |                 |  |  |
| subjects affected / exposed                     | 2 / 19 (10.53%) |  |  |
| occurrences (all)                               | 3               |  |  |
| Epistaxis                                       |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 2               |  |  |
| Psychiatric disorders                           |                 |  |  |
| Insomnia  |                 |  |  |
| subjects affected / exposed                     | 4 / 19 (21.05%) |  |  |
| occurrences (all)                               | 5               |  |  |
| Investigations                                  |                 |  |  |
| Gamma-glutamyltransferase increased             |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 2               |  |  |
| Transaminases increased                         |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 2               |  |  |
| Alanine aminotransferase increased              |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Blood cholesterol increased                     |                 |  |  |

|  |                     |  |  |
|--|---------------------|--|--|
| subjects affected / exposed<br>occurrences (all) | 1 / 19 (5.26%)<br>1 |  |  |
| Nervous system disorders                         |                     |  |  |
| Headache   |                     |  |  |
| subjects affected / exposed                      | 2 / 19 (10.53%)     |  |  |
| occurrences (all)                                | 3                   |  |  |
| Sciatica   |                     |  |  |
| subjects affected / exposed                      | 1 / 19 (5.26%)      |  |  |
| occurrences (all)                                | 1                   |  |  |
| Blood and lymphatic system disorders             |                     |  |  |
| Anaemia  |                     |  |  |
| subjects affected / exposed                      | 1 / 19 (5.26%)      |  |  |
| occurrences (all)                                | 1                   |  |  |
| Microcytosis                                     |                     |  |  |
| subjects affected / exposed                      | 1 / 19 (5.26%)      |  |  |
| occurrences (all)                                | 1                   |  |  |
| Eye disorders                                    |                     |  |  |
| Conjunctivitis                                   |                     |  |  |
| subjects affected / exposed                      | 2 / 19 (10.53%)     |  |  |
| occurrences (all)                                | 2                   |  |  |
| Chalazion  |                     |  |  |
| subjects affected / exposed                      | 1 / 19 (5.26%)      |  |  |
| occurrences (all)                                | 1                   |  |  |
| Eyelid oedema                                    |                     |  |  |
| subjects affected / exposed                      | 1 / 19 (5.26%)      |  |  |
| occurrences (all)                                | 1                   |  |  |
| Gastrointestinal disorders                       |                     |  |  |
| Aphthous ulcer                                   |                     |  |  |
| subjects affected / exposed                      | 7 / 19 (36.84%)     |  |  |
| occurrences (all)                                | 11                  |  |  |
| Diarrhoea  |                     |  |  |
| subjects affected / exposed                      | 4 / 19 (21.05%)     |  |  |
| occurrences (all)                                | 4                   |  |  |
| Dysgeusia  |                     |  |  |
| subjects affected / exposed                      | 2 / 19 (10.53%)     |  |  |
| occurrences (all)                                | 3                   |  |  |
| Abdominal pain upper                             |                     |  |  |

|  |                 |  |  |
|--|-----------------|--|--|
| subjects affected / exposed            | 2 / 19 (10.53%) |  |  |
| occurrences (all)                      | 2               |  |  |
| Vomiting                               |                 |  |  |
| subjects affected / exposed            | 2 / 19 (10.53%) |  |  |
| occurrences (all)                      | 2               |  |  |
| Gingival abscess                       |                 |  |  |
| subjects affected / exposed            | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                      | 1               |  |  |
| Dry mouth                              |                 |  |  |
| subjects affected / exposed            | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                      | 1               |  |  |
| Gastrointestinal pain                  |                 |  |  |
| subjects affected / exposed            | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                      | 1               |  |  |
| Stomatitis                             |                 |  |  |
| subjects affected / exposed            | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                      | 1               |  |  |
| Constipation                           |                 |  |  |
| subjects affected / exposed            | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                      | 1               |  |  |
| Gastroenteritis                        |                 |  |  |
| subjects affected / exposed            | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                      | 1               |  |  |
| Gingival bleeding                      |                 |  |  |
| subjects affected / exposed            | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                      | 1               |  |  |
| Odynophagia                            |                 |  |  |
| subjects affected / exposed            | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                      | 1               |  |  |
| Hepatobiliary disorders                |                 |  |  |
| Hepatotoxicity                         |                 |  |  |
| subjects affected / exposed            | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                      | 1               |  |  |
| Skin and subcutaneous tissue disorders |                 |  |  |
| Dermatitis acneiform                   |                 |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed                     | 3 / 19 (15.79%) |  |  |
| occurrences (all)                               | 5               |  |  |
| Dermatitis                                      |                 |  |  |
| subjects affected / exposed                     | 2 / 19 (10.53%) |  |  |
| occurrences (all)                               | 2               |  |  |
| Erythema  |                 |  |  |
| subjects affected / exposed                     | 2 / 19 (10.53%) |  |  |
| occurrences (all)                               | 2               |  |  |
| Rash  |                 |  |  |
| subjects affected / exposed                     | 2 / 19 (10.53%) |  |  |
| occurrences (all)                               | 2               |  |  |
| Alopecia  |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Rash maculo-papular                             |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Pruritus  |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Renal and urinary disorders                     |                 |  |  |
| Polyuria  |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Proteinuria                                     |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Musculoskeletal and connective tissue disorders |                 |  |  |
| Back pain                                       |                 |  |  |
| subjects affected / exposed                     | 2 / 19 (10.53%) |  |  |
| occurrences (all)                               | 2               |  |  |
| Myalgia   |                 |  |  |
| subjects affected / exposed                     | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                               | 2               |  |  |
| Arthralgia                                      |                 |  |  |

|                                    |                 |  |  |
|------------------------------------|-----------------|--|--|
| subjects affected / exposed        | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Neck pain                          |                 |  |  |
| subjects affected / exposed        | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Muscle spasms                      |                 |  |  |
| subjects affected / exposed        | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Infections and infestations        |                 |  |  |
| Urinary tract infection            |                 |  |  |
| subjects affected / exposed        | 2 / 19 (10.53%) |  |  |
| occurrences (all)                  | 8               |  |  |
| Oral herpes                        |                 |  |  |
| subjects affected / exposed        | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                  | 2               |  |  |
| Gingivitis                         |                 |  |  |
| subjects affected / exposed        | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Herpes zoster                      |                 |  |  |
| subjects affected / exposed        | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Ear lobe infection                 |                 |  |  |
| subjects affected / exposed        | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Respiratory tract infection        |                 |  |  |
| subjects affected / exposed        | 1 / 19 (5.26%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Metabolism and nutrition disorders |                 |  |  |
| Hypercholesterolaemia              |                 |  |  |
| subjects affected / exposed        | 9 / 19 (47.37%) |  |  |
| occurrences (all)                  | 11              |  |  |
| Hypertriglyceridaemia              |                 |  |  |
| subjects affected / exposed        | 5 / 19 (26.32%) |  |  |
| occurrences (all)                  | 8               |  |  |
| Decreased appetite                 |                 |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 1 / 19 (5.26%) |  |  |
| occurrences (all)           | 1              |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported